Q3
COR — Q3 2026 Financial Report Analysis
Cencora's fiscal Q3 2026 revenue rose 5.1% to $84.8B on GLP-1 and specialty drug volume. The OneOncology acquisition and a $102M opioid-liability credit lifted GAAP operating income 29.1% and EPS 11.9% to $3.94, and adjusted EPS guidance rose to $17.75–$17.95.